U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H24N2O4S.ClH
Molecular Weight 364.888
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIAPRIDE HYDROCHLORIDE

SMILES

Cl.CCN(CC)CCNC(=O)C1=C(OC)C=CC(=C1)S(C)(=O)=O

InChI

InChIKey=OTFDPNXIVHBTKW-UHFFFAOYSA-N
InChI=1S/C15H24N2O4S.ClH/c1-5-17(6-2)10-9-16-15(18)13-11-12(22(4,19)20)7-8-14(13)21-3;/h7-8,11H,5-6,9-10H2,1-4H3,(H,16,18);1H

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C15H24N2O4S
Molecular Weight 328.427
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Tiapride is a drug that selectively blocks D2 and D3 dopamine receptors in the brain. It is used to treat a variety of neurological and psychiatric disorders including dyskinesia, alcohol withdrawal syndrome, negative symptoms of psychosis, and agitation and aggression in the elderly. A derivative of benzamide, tiapride is chemically and functionally similar to other benzamide antipsychotics such as sulpiride and amisulpride known for their dopamine antagonist effects. Tiapride is marketed under various trade names and is widely available outside of the United States. The most common trade name for tiapride is Tiapridal, which is used throughout Europe, Russia, as well as parts of South America, the Middle East, and North Africa. It is also sold under different names in Italy (Italprid, Sereprile), Japan (Tialaread, Tiaryl, Tiaprim, Tiaprizal), Chile (Sereprid), Germany (Tiaprid, Tiapridex), and China (Tiapride).

CNS Activity

CNS Active
3,913

Originator

Sanofi-Synthelabo
26

Approval Year

Unknown
139,594

Targets

Primary TargetPharmacologyConditionPotency
Dopamine D2 receptor
297
Antagonist
2,778
 45.8 µM [IC50]
dopamine receptor D4
2
Antagonist
2,778
 11.7 µM [IC50]
Dopamine D3 receptor
91
Antagonist
2,778
 180.0 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Tardive dyskinesia
15
 Primary
Approved
8,429
Tiacob
Huntington's disease
24
 Primary
Phase III
656
Unknown
Tourette's syndrome
20
 Primary
Phase III
656
Unknown

PubMed

Patents

06861072
2
JP2001523241A
2
JPH08512055A
14

Sample Use Guides

In Vivo Use Guide
Adults should take 100 – 200 mg tiapride three times daily, depending on the severity of the disease and the body weight of the individual . The proposed daily dose for the claimed indication is 300 – 600 mg tiapride. The effect of treatment may not be apparent until after a period of 4-6 weeks of treatment. Tiapride tablets should preferably be taken with a little liquid after meals.
Route of Administration: Oral
In Vitro Use Guide
Tiapride increased the potential for half-maximal activation (V(1/2)) of HERG at 10~300 uM. In guinea pig ventricular myocytes, bath applications of 100 and 500 uM tiapride at 36℃ blocked rapidly activating delayed rectifier K(+) current (I(Kr)) by 40.3% and 70.0%, respectively.
Substance Class Chemical
Record UNII
25N106WEDO
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966